J. Anderson

发表

Stress and Immunity in Humans: Modifying Variables

Julie A. Anderson, N. Hall, M. O'Grady, 1994 .

Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial

F. Martinez, P. Calverley, D. Niewoehner, 2018, American journal of respiratory and critical care medicine.

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

R. Pauwels, A. Gulsvik, N. Pride, 2003, The Lancet.

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

Bartolome Celli, Christine Jenkins, C. Jenkins, 2007, The New England journal of medicine.

Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.

F. Martinez, R. Brook, B. Celli, 2017, Respiratory medicine.

The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol

F. Martinez, P. Calverley, R. Brook, 2012, European Respiratory Journal.

Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study

P. Calverley, C. Jenkins, B. Celli, 2011, The clinical respiratory journal.

Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review

F. Martinez, P. Calverley, B. Celli, 2020, American journal of respiratory and critical care medicine.

Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial

F. Martinez, P. Calverley, R. Brook, 2016, The Lancet.

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

Robert A Wise, Julie A. Anderson, R. Wise, 2007, Thorax.

Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience.

P. Calverley, C. Jenkins, B. Celli, 2010, American journal of respiratory and critical care medicine.

Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial

James Brian Byrd, F. Martinez, P. Calverley, 2018, European heart journal.

Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial

V. Kim, F. Martinez, P. Calverley, 2019, BMJ Open Respiratory Research.

Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial

F. Martinez, P. Calverley, R. Brook, 2021, ERJ Open Research.

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change

Christine Jenkins, C. Jenkins, B. Celli, 2011, Respiratory research.

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

C. Jenkins, B. Celli, J. Vestbo, 2009, Respiratory research.

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.

P. Calverley, C. Jenkins, B. Celli, 2008, American journal of respiratory and critical care medicine.

A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo.

D. Postma, A. Buist, N. Anthonisen, 2007, Chest.

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease

F. Martinez, P. Calverley, R. Brook, 2018, Journal of the American College of Cardiology.

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk

F. Martinez, R. Brook, S. Rajagopalan, 2017, Heart.

Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial

D. Niewoehner, J. Yates, P. Amarenco, 2020, Clinical trials.

Cardiovascular events in patients with COPD: TORCH Study results

C. Jenkins, B. Celli, J. Vestbo, 2010, Thorax.

Regional differences in rate of FEV1 decline in COPD: lessons from SUMMIT

F. Martinez, P. Calverley, R. Brook, 2019, European Respiratory Journal.

Impact of pre-enrolment medication use on clinical outcomes in SUMMIT

P. Calverley, R. Brook, B. Celli, 2019, ERJ Open Research.

Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.

R. Pauwels, P. Calverley, J. Soriano, 2004, Respiratory medicine.

Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study

O. Keene, Julie A. Anderson, Mark R Jones, 2007, Pharmaceutical statistics.

FEV1 is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease

F. Martinez, P. Calverley, R. Brook, 2020, International journal of chronic obstructive pulmonary disease.

Long-Acting β-Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial.

F. Martinez, P. Calverley, R. Brook, 2018, American journal of respiratory and critical care medicine.

Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk

F. Martinez, R. Brook, B. Celli, 2018, American journal of respiratory and critical care medicine.